

Special Issue

Safety and Immunogenicity of Vaccination

Message from the Guest Editor

Vaccination remains one of the most transformative public health interventions. This Special Issue aims to collate cutting-edge research, clinical trial outcomes, and mechanistic insights into vaccine-induced immune responses. The issue will serve to guide those working to ensure the safety and effectiveness of vaccines, especially in the context of vaccine preparedness. We welcome original articles, systematic reviews, and short communications that address:

- Preclinical and clinical safety profiles of emerging vaccine candidates;
- Kinetics and quality of immune responses (e.g., durability, breadth, avidity);
- Correlates of protection across different vaccine platforms;
- Comparative immunogenicity across age groups, immunocompromised individuals, and special populations;
- Biomarkers for vaccine efficacy and adverse events;
- Innovations in vaccine formulation, delivery, and adjuvant systems.

This issue will serve as a reference point for scientists, regulators, and policymakers working to ensure the **safety and effectiveness of next-generation vaccines**, particularly in the context of pandemic preparedness and global equity.

Guest Editor

Dr. Jennifer Serwanga

1. Department of Immunology, Uganda Virus Research Institute, Entebbe P.O. Box 49, Uganda
2. Medical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda
3. London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/244077

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).